Abstract: Previously, Alzheimer’s disease was called rare chronic neurodegenerative disorder that, now these days, gets worse over time and non-curable. And, it has been considered as a major public health issue that is seriously affecting millions of peoples in America, Western Europe and other Asian countries followed by in Sub-Saharan Africa. Alzheimer’s disease is caused due to formation of amyloid-beta (Aβ) plaques in brain, which lead to accumulation of neurotoxic cerebrovascular lesions that damaging connections of one neuron to another whose main causes are due to stressful life of modern-era or sometimes. It may be also drug induced medicated therapies or drug addiction. One more protein called "Tau protein" is accumulated as stable tangles inside neurons leading to the neural cells death in brain. Dementia associated with Alzheimer’s Disease (AD) is directly linked with the formation of amyloid-beta plaques and Tau protein observed in patients’ brain by PET/CT scan. Existing therapies for Alzheimer’s disease are often provided patients with some symptomatic relief form onset of symptoms including memory loss and decline any intellectual ability for a short interval of time. However, there are no current curable treatments that change the underlying process of this disease and slow down its progression. So now, cholinesterase inhibitors e.g., Donepezil, Rivastigmine, Physostigmine are prescribed to treat symptoms of Alzheimer’s disease related to loss in judgment, memory, thinking, language and other thought processes. These used drugs are worked by increasing the level of acetylcholine, which is chemical messenger involved to regulate all type of thought processes. An N-methyl-D-aspartate receptor (NMDA receptor) antagonist such as Memantine is used to control the synaptic plasticity and memory function to work as glutamatergic pathway to block excessive release glutamate via blocking NDMA receptors. Generally, cholinesterase inhibitors and Memantine can be used for safe therapeutic medication with excellent efficacy for the treatment of patients suffering from Alzheimer’s disease. So, form this brief preview, we can get the possible frameworks to carry out the more potential and efficient clinical management strategies including effective diagnostics advanced approaches and drug targeted therapies to treat this disease. It might be lead to deceased mortality and morbidity rate of the affected individuals worldwide.